MiR-375 is upregulated in acquired paclitaxel resistance in cervical cancer

British Journal of Cancer

Volumn 109, Issue 1, 2013, Pages 92-99

  Shen, Y ^a   Wang, P ^a   Li, Y ^a   Ye, F ^a   Wang, F ^a   Wan, X ^a   Cheng, X ^a   Lu, W ^a   Xie, X ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; LENTIVIRUS VECTOR; MICRORNA; MICRORNA 181B; MICRORNA 224; MICRORNA 27A; MICRORNA 375; MICRORNA 424; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SIZE; CANCER SURGERY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STABLE EXPRESSION; TISSUE MICROARRAY; UPREGULATION; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; PACLITAXEL; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84880288028     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.308     Document Type: Article

References (36)

1. Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA (2013) Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents. Oncology 84: 158-165.
2. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, Liu M, Chen CT, Yu D, Hung MC (2011) p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13: 317-323.
3. de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, Malekpour F, Volinia S, Croce CM, Najmabadi H, Diederichs S, Sahin O, Mayer D, Lyko F, Hoheisel JD, Riazalhosseini Y (2010) Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 70: 9175-9184.
4. Bolstad BM, Irizarry RA, Astrandand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics19 185-193.
5. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
6. Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, Liu X, Ke Y, Si J, Zhou T (2010) MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20: 784-793.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
8. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H, Song E (2011) Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 286: 19127-19137.
9. Guo L, Liu Y, Bai Y, Sun Y, Xiao F, Guo Y (2010) Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 46: 1692-1702.
10. Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W, Perez- Ordonez B, Jurisica I, O'Sullivan B, Waldron J, Gullane P, Cummings B, Liu FF (2010) Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 16: 1129-1139.
11. Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ, Green JE (2011) miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 4: 79.
12. Lajer CB, Nielsen FC, Friis-Hansen L, Norrild B, Borup R (2011) Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. Br J Cancer 104: 830-840.
13. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY (2010) Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV positive hepatocarcinoma. Cancer Res 70: 9798-9807.
14. Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J, Lu W, Wan X, Ma D, Xie X (2011) Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol 224: 484-495.
15. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast Jr. RC (2008) The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 118: 3917-3929.
16. Mazar J, DeBlasio D, Govindarajan SS, Zhang S, Perera RJ (2011) Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS Lett 585: 2467-2476.
17. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T (2006) Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130: 2113-2129.
18. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M, Ju J (2006) Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 3: 317-324.
19. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, Rorsman P, Zavolan M, Stoffel M (2009) miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci USA 106: 5813-5818.
20. Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA (2006) Functional coupling of p38-induced up-regulation of BiP and activation of RNAdependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 66: 1702-1711.
21. Ren Y, Zhou X, Mei M, Yuan XB, Han L, Wang GX, Jia ZF, Xu P, Pu PY, Kang CS (2010) MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 10: 27.
22. Szczyrba J, Nolte E, Wach S, Kremmer E, Stohr R, Hartmann A, Wieland W, Wullich B, Grasser FA (2011) Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol Cancer Res 9: 791-800.
23. Tanaka T, Toujima S, Tanaka J (2012) Differential sensitivity to paclitaxelinduced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells. Int J Oncol 41: 1837-1844.
24. Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, Moriyama M (2010) MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 70: 2339-2349.
25. Wang F, Li Y, Zhou J, Xu J, Peng C, Ye F, Shen Y, Lu W, Wan X, Xie X (2011) miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol 179: 2580-2588.
26. Wang JW, Cheng JQ (2008) A simple method for profiling miRNA expression. Methods Mol Biol 414: 183-190.
27. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH (2010) Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 13: 109-118.
28. Ward A, Balwierz A, Zhang JD, Ku?blbeck M, Pawitan Y, Hielscher T, Wiemann S, Sahin O (2013) Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 32: 1173-1182.
29. Wendt MK, Smith JA, Schiemann WP (2010) Transforming growth factorbeta- induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 29: 6485-6498.
30. Wilson CM, Tobin S, Young RC (2004) The exploding worldwide cancer burden: the impact of cancer on women. Int J Gynecol Cancer 14 1-11.
31. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham D, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) An ad hoc committee of the National Cancer Research Institute Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
32. Wu X, Xiao H (2009) miRNAs modulate the drug response of tumor cells. Sci China C Life Sci 52: 797-801.
33. Yavas G, Yavas C (2012) Comment on 'Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study' by Ferrandina et al. (GYNECOL ONCOL 2012; 124:389-394). Gynecol Oncol 126: 167 author reply 167-168.
34. Yu Y, Zhu Z (2013) Cell dormancy and tumor refractory. Anticancer Agents Med Chem 13: 199-202.
35. Yu L, Todd NW, Xing L, Xie Y, Zhang H (2010) Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 127: 2870-2878.
36. Zou Z, Wu L, Ding H, Wang Y, Zhang Y, Chen X, Zhang CY, Zhang Q, Zen K (2012) MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J Biol Chem 287: 4148-4156.